On the potential role of intestinal microbial community in hepatocarcinogenesis in chronic hepatitis B

Cancer Medicine

Volumn 7, Issue 7, 2018, Pages 3095-3100

  Mohamadkhani, Ashraf ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Escherichia coli; HBV carrier patients; hepatocellular carcinoma; intestinal microbiota; lipopolysaccharide

Indexed keywords

BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CHRONIC HEPATITIS B; CHRONIC INFLAMMATION; CLOSTRIDIUM; CLOSTRIDIUM PERFRINGENS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FAECALIBACTERIUM PRAUSNITZII; HUMAN; HYDROLYSIS; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOSTIMULATION; INNATE IMMUNITY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MICROBIAL COMMUNITY; OUTCOME ASSESSMENT; PEPTOCLOSTRIDIUM DIFFICILE; PREDICTION; PRIORITY JOURNAL; REVIEW; VEILLONELLA; VIRULENCE;

EID: 85047516392     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.1550     Document Type: Review

References (54)

1. Kang Y, Cai Y. Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy. J Hosp Infect. 2017;96:342-348.
2. Alexopoulou A, Agiasotelli D, Vasilieva LE, Dourakis SP. Bacterial translocation markers in liver cirrhosis. Ann Gastroenterol. 2017;30:486-497.
3. Mohamadkhani A, Sayemiri K, Ghanbari R, Elahi E, Poustchi H, Montazeri G. The inverse association of serum HBV DNA level with HDL and adiponectin in chronic hepatitis B infection. Virol J. 2010;7:228.
4. Li DK, Yan P, Abou-Samra AB, Chung RT, Butt AA. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES. Aliment Pharmacol Ther. 2018;47:246-258.
5. Moradzadeh M, Tayebi S, Poustchi H, et al. The possible role of TLR2 in chronic hepatitis B patients with precore mutation. Adv Virol. 2013;2013:780319.
6. Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol. 2011;61:693-703.
7. Gundogdu A, Nalbantoglu U. Human genome-microbiome interaction: metagenomics frontiers for the aetiopathology of autoimmune diseases. Microb Genom. 2017;3:e000112.
8. Low JSY, Soh SE, Lee YK, et al. Ratio of Klebsiella/Bifidobacterium in early life correlates with later development of paediatric allergy. Benef Microbes. 2017;8:681-695.
9. Ehrlich SD. The human gut microbiome impacts health and disease. CR Biol. 2016;339:319-323.
10. Madsen BS, Havelund T, Krag A. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective beta-blockers. Adv Ther. 2013;30:659-670.
11. Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci USA. 2003;100:10452-10459.
12. Rajilic-Stojanovic M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014;38:996-1047.
13. Sankar SA, Lagier JC, Pontarotti P, Raoult D, Fournier PE. The human gut microbiome, a taxonomic conundrum. Syst Appl Microbiol. 2015;38:276-286.
14. Wang J, Wang Y, Zhang X, et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients. Front Microbiol. 2017;8:2222.
15. Roderburg C, Luedde T. The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. Gut Microbes. 2014;5:441-445.
16. Zhang HL, Yu LX, Yang W, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol. 2012;57:803-812.
17. Grat M, Wronka KM, Krasnodebski M, et al. Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis. Transpl Proc. 2016;48:1687-1691.
18. Wu ZW, Lu HF, Wu J, et al. Assessment of the fecal lactobacilli population in patients with hepatitis B virus-related decompensated cirrhosis and hepatitis B cirrhosis treated with liver transplant. Microb Ecol. 2012;63:929-937.
19. Tao X, Wang N, Qin W. Gut microbiota and hepatocellular carcinoma. Gastrointestinal Tumors. 2015;2:33-40.
20. Xu M, Wang B, Fu Y, et al. Changes of fecal Bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease. Microb Ecol. 2012;63:304-313.
21. Moratalla A, Gomez-Hurtado I, Santacruz A, et al. Protective effect of Bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis. Liver Int. 2014;34:850-858.
22. Zheng X, Qiu Y, Zhong W, et al. A targeted metabolomic protocol for short-chain fatty acids and branched-chain amino acids. Metabolomics. 2013;9:818-827.
23. Cremer J, Arnoldini M, Hwa T. Effect of water flow and chemical environment on microbiota growth and composition in the human colon. Proc Natl Acad Sci USA. 2017;114:6438-6443.
24. Jiminez JA, Uwiera TC, Abbott DW, Uwiera RRE, Inglis GD. Impacts of resistant starch and wheat bran consumption on enteric inflammation in relation to colonic bacterial community structures and short-chain fatty acid concentrations in mice. Gut Pathog. 2016;8:67.
25. Li H, Gao Z, Zhang J, et al. Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes. 2012;61:797-806.
26. Hijova E, Chmelarova A. Short chain fatty acids and colonic health. Bratisl Lek Listy. 2007;108:354-358.
27. Rios-Covian D, Ruas-Madiedo P, Margolles A, Gueimonde M, de Los Reyes-Gavilan CG, Salazar N. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol. 2016;7:185.
28. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013;29:264-270.
29. Sozinov AS. Systemic endotoxemia during chronic viral hepatitis. Bull Exp Biol Med. 2002;133:153-155.
30. Imani Fooladi AA, Mahmoodzadeh Hosseini H, Nourani MR, Khani S, Alavian SM. Probiotic as a novel treatment strategy against liver disease. Hepat Mon. 2013;13:e7521.
31. Pan C, Gu Y, Zhang W, et al. Dynamic changes of lipopolysaccharide levels in different phases of acute on chronic hepatitis B liver failure. PLoS ONE. 2012;7:e49460.
32. Giannelli V, Di Gregorio V, Iebba V, et al. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol. 2014;20:16795-16810.
33. Palsson-McDermott EM, O’Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology. 2004;113:153-162.
34. Ma Z, Zhang E, Yang D, Lu M. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol. 2015;12:273-282.
35. Zhang E, Lu M. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol. 2015;204:11-20.
36. Isayama F, Hines IN, Kremer M, et al. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1318-G1328.
37. Wei X, Yan X, Zou D, et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach. BMC Gastroenterol. 2013;13:175.
38. Hill CJ, Lynch DB, Murphy K, et al. Evolution of gut microbiota composition from birth to 24 weeks in the INFANTMET Cohort. Microbiome. 2017;5:4.
39. Kryger J, Burleigh A, Christensen M, Hopkins W. Genetic evaluation of E. coli strains isolated from asymptomatic children with neurogenic bladders. Int J Chronic Dis. 2015;2015:206570.
40. Park HK, Shim SS, Kim SY, et al. Molecular analysis of colonized bacteria in a human newborn infant gut. J Microbiol. 2005;43:345-353.
41. Payros D, Secher T, Boury M, et al. Maternally acquired genotoxic Escherichia coli alters offspring’s intestinal homeostasis. Gut Microbes. 2014;5:313-325.
42. Bidet P, Metais A, Mahjoub-Messai F, et al. Detection and identification by PCR of a highly virulent phylogenetic subgroup among extraintestinal pathogenic Escherichia coli B2 strains. Appl Environ Microbiol. 2007;73:2373-2377.
43. Nowrouzian FL, Adlerberth I, Wold AE. Enhanced persistence in the colonic microbiota of Escherichia coli strains belonging to phylogenetic group B2: role of virulence factors and adherence to colonic cells. Microbes Infect. 2006;8:834-840.
44. Hoseinzadeh T, Ghanbarpour R, Rokhbakhsh-Zamin F. Phylogenetic background of enterotoxigenic and enteroinvasive Escherichia coli from patients with diarrhea in Sirjan, Iran. Iran J Microbiol. 2016;8:187-192.
45. Taieb F, Nougayrede JP, Watrin C, Samba-Louaka A, Oswald E. Escherichia coli cyclomodulin Cif induces G2 arrest of the host cell cycle without activation of the DNA-damage checkpoint-signalling pathway. Cell Microbiol. 2006;8:1910-1921.
46. Taieb F, Petit C, Nougayrede JP, Oswald E. The enterobacterial genotoxins: cytolethal distending toxin and colibactin. EcoSal Plus. 2016;7:ESP-0008-2016.
47. Mohamadkhani A, Katoonizadeh A, Poustchi H. Immune-regulatory events in the clearance of HBsAg in chronic hepatitis B: focuses on HLA-DP. Middle East J Dig Dis. 2015;7:5-13.
48. Mohamadkhani A, Bastani F, Sotoudeh M, et al. Influence of B cells in liver fibrosis associated with hepatitis B virus harboring basal core promoter mutations. J Med Virol. 2012;84:1889-1896.
49. Besharat S, Katoonizadeh A, Moossavi S, et al. The possible impact of sortilin in reducing HBsAg expression in chronic hepatitis B. J Med Virol. 2016;88:647-652.
50. Leimbach A, Hacker J, Dobrindt U. E. coli as an all-rounder: the thin line between commensalism and pathogenicity. Curr Top Microbiol Immunol. 2013;358:3-32.
51. Thorgersen EB, Pharo A, Haverson K, et al. Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood. Infect Immun. 2009;77:725-732.
52. Wu J, Lu M, Meng Z, et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology. 2007;46:1769-1778.
53. Tayebi S, Mohamadkhani A. The TNF-alpha -308 promoter gene polymorphism and chronic HBV infection. Hepat Res Treat. 2012;2012:493219.
54. Li W, Xiao J, Zhou X, et al. STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma. J Clin Investig. 2015;125:4239-4254.